Search Result

Results for "

LHRH receptors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenylate Cyclase (1) GnRH Receptor (10) Peptide-Drug Conjugates (PDCs) (1) PTHR (1)
By Research Areas:	Cancer (4) Endocrinology (8) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-P1852

TIP 39, Tuberoinfundibular Neuropeptide 1 Publications Verification	Adenylate Cyclase PTHR	Neurological Disease
TIP 39, Tuberoinfundibular Neuropeptide is an endogenous PTH2 receptor agonist and antihypertensive agent. TIP 39, Tuberoinfundibular Neuropeptide selectively activates the PTH2 receptor with no activity on the PTH1 receptor, stimulates cAMP production, activates adenylate cyclase, and elevates intracellular calcium levels via mobilization from intracellular stores. TIP 39, Tuberoinfundibular Neuropeptide is highly conserved in humans, mice, and rats. TIP 39, Tuberoinfundibular Neuropeptide is applicable to research related to nociception and inflammation-induced pain .

HY-100209

Sufugolix TAK-013	GnRH Receptor	Endocrinology
Sufugolix (TAK-013) is a highly potent and orally available luteinizing hormone-releasing hormone (LHRH) receptor antagonist with an IC₅₀ of 0.1 nM.

HY-16532

Zoptarelin doxorubicin AEZS-108; AN-152	Peptide-Drug Conjugates (PDCs) GnRH Receptor	Cancer
Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptarelin doxorubicin has been used to research targeting tumors expressing **LHRH receptors. Zoptarelin doxorubicin abolishes tumor progression and induces remarkable apoptosis** in vitro .

HY-P3668

[D-Lys6]-LH-RH	GnRH Receptor	Endocrinology Cancer
[D-Lys6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Lys6]-LH-RH acts as a GnRH receptor agonist .

HY-P3668A

[D-Lys6]-LH-RH TFA	GnRH Receptor	Endocrinology Cancer
[D-Lys6]-LH-RH TFA is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Lys6]-LH-RH TFA acts as a GnRH receptor agonist .

HY-P3672

[D-Ala6]-LH-RH	GnRH Receptor	Endocrinology
[D-Ala6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Ala6]-LH-RH acts as a GnRH receptor agonist .

HY-P2028

BIM 21009	GnRH Receptor	Cancer
BIM 21009 is a *LHRH* and GnRH receptor antagonist. BIM 21009 inhibits tumor growth .

HY-P2110

RS-18286	GnRH Receptor	Endocrinology
RS-18286 is a potent luteinizing-hormone (LH)-releasing hormone (LHRH) antagonist. RS-18286 blocks the pituitary LHRH receptor and suppresses pituitary luteinizing-hormone (LH) secretion and reduce serum concentrations of gonadal steroids .

HY-P3671

[D-Glp1,D-Phe2,D-Trp3,6]-LH-RH	GnRH Receptor	Endocrinology
[D-Glp1,D-Phe2,D-Trp3,6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH acts as a GnRH receptor antagonist .

HY-107533

T-98475	GnRH Receptor	Endocrinology
T-98475 (Compound 26d) is a potent, orally active, non-peptide luteinizing hormone-releasing hormone (LHRH) receptor antagonist with an IC₅₀ of 0.2 nM .

HY-P2446

ORG 30276 APTAA-LHRH	GnRH Receptor	Endocrinology
ORG 30276 (APTAA-LHRH) is a potent GnRH antagonist that effectively reduces serum LH and FSH levels in male rats. ORG 30276 significantly decreases unoccupied pituitary GnRH receptors, leading to suppressed gonadotropin secretion. ORG 30276 treatment results in a considerable reduction in mRNA levels of gonadotropin beta-subunits in the pituitary gland. ORG 30276's effects on gonadotropin dynamics can be selectively reversed by the replacement of specific sex steroids, with androgens being particularly effective for the FSH beta-subunit mRNA levels.

Cat. No.	Nombre del producto	Target	Research Area

HY-P1852

TIP 39, Tuberoinfundibular Neuropeptide 1 Publications Verification	Adenylate Cyclase PTHR	Neurological Disease
TIP 39, Tuberoinfundibular Neuropeptide is an endogenous PTH2 receptor agonist and antihypertensive agent. TIP 39, Tuberoinfundibular Neuropeptide selectively activates the PTH2 receptor with no activity on the PTH1 receptor, stimulates cAMP production, activates adenylate cyclase, and elevates intracellular calcium levels via mobilization from intracellular stores. TIP 39, Tuberoinfundibular Neuropeptide is highly conserved in humans, mice, and rats. TIP 39, Tuberoinfundibular Neuropeptide is applicable to research related to nociception and inflammation-induced pain .

HY-16532

Zoptarelin doxorubicin AEZS-108; AN-152	Peptide-Drug Conjugates (PDCs) GnRH Receptor	Cancer
Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptarelin doxorubicin has been used to research targeting tumors expressing **LHRH receptors. Zoptarelin doxorubicin abolishes tumor progression and induces remarkable apoptosis** in vitro .

HY-P3668

[D-Lys6]-LH-RH	GnRH Receptor	Endocrinology Cancer
[D-Lys6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Lys6]-LH-RH acts as a GnRH receptor agonist .

HY-P3668A

[D-Lys6]-LH-RH TFA	GnRH Receptor	Endocrinology Cancer
[D-Lys6]-LH-RH TFA is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Lys6]-LH-RH TFA acts as a GnRH receptor agonist .

HY-P3672

[D-Ala6]-LH-RH	GnRH Receptor	Endocrinology
[D-Ala6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Ala6]-LH-RH acts as a GnRH receptor agonist .

HY-P2028

BIM 21009	GnRH Receptor	Cancer
BIM 21009 is a *LHRH* and GnRH receptor antagonist. BIM 21009 inhibits tumor growth .

HY-P2110

RS-18286	GnRH Receptor	Endocrinology
RS-18286 is a potent luteinizing-hormone (LH)-releasing hormone (LHRH) antagonist. RS-18286 blocks the pituitary LHRH receptor and suppresses pituitary luteinizing-hormone (LH) secretion and reduce serum concentrations of gonadal steroids .

HY-P3671

[D-Glp1,D-Phe2,D-Trp3,6]-LH-RH	GnRH Receptor	Endocrinology
[D-Glp1,D-Phe2,D-Trp3,6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH acts as a GnRH receptor antagonist .

HY-P2446

ORG 30276 APTAA-LHRH	GnRH Receptor	Endocrinology
ORG 30276 (APTAA-LHRH) is a potent GnRH antagonist that effectively reduces serum LH and FSH levels in male rats. ORG 30276 significantly decreases unoccupied pituitary GnRH receptors, leading to suppressed gonadotropin secretion. ORG 30276 treatment results in a considerable reduction in mRNA levels of gonadotropin beta-subunits in the pituitary gland. ORG 30276's effects on gonadotropin dynamics can be selectively reversed by the replacement of specific sex steroids, with androgens being particularly effective for the FSH beta-subunit mRNA levels.

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
E-mail *

	Sorry, but the email address you supplied was invalid.